Dramaturgie des Schauspiels,

Vol. 1-2 appeared originally under title: Dramaturgie der Classiker, 1882-83.

Thomas Carlyle's works.

Cited in Dyer, I.W. A bibl. of T. Carlyle's writings and ana. 1968. p.59.

Abhandlungen des Wirtschaftswissenschaftlichen Seminars zu Jena

Mode of access: Internet.

Sa mtliche werke ... /

1. bd. Gedichte.--2. bd. Die Ra uber. Die verschwo rung des Fiesco zu Genua. Kabale und liebe.--3. bd. Don Karlos, Semele. Der menschenfeind.--4. bd. Wallensteins lager. Die Piccolomini. Wallensteins tod.--5. bd. Maria Stuart. Die junfrau von Orleans.--6. bd. Wilhelm Tell. Die huldigung der Ku nste.--Die braut von Messina.--7.-8. bd. Uebersetzungen.--9. bd. Geschichte des abfalls der vereinigten Niederlande von der spanischen regierung.--10-11. bd. Geschichte des dreissigjahrigen kriegs.--12. bd. Prosaische schriften (1 und. 2. periode).--13-14. bd. Kleine schriften vermischten inhalts, I-II.--15. bd. Kleine schriften vermischten inhalts. II.--16. bd. Dramatischer nachlass.

Humanism; philosophical essays,

The ethical basis of metaphysics.--'Useless' knowledge.--Truth.--Lotze's monism.--Non-Euclidean geometry and the Kantian a priori.--The metaphysics ofthe time-process.--Reality and 'idealism.'--Darwinism and design.--The place of pessimism in philosophy.--Concerning Mephistopheles.--On preserving appearances.--Activity and substance.--Humism and humanism.--Solipsism.--Infallibility and toleration.--Freedom and responsibility.--The desire for immortality.--The ethical significance of immortality.--Philosophy and the scientific investigation of a future life.

Studies in humanism /

"Of the essays which compose this volume about half have appeared in various periodicals, Mind, The Hibbert Journal, The Quarterly Review, The Fortnightly Review, and The Journal of Philosophy, during the past three years."- Pref.

Werke.

Mode of access: Internet.

Mélanges historiques et littéraires.

Mode of access: Internet.

Schillers Werke /

Includes indexes.

Cervical Cancer Control, Priorities and New Directions

Cervical cancer is caused by infection with a range of high risk oncogenic human papillomavirus (HPV) types, and it is now accepted that >99% of cervical cancer is initiated by HPV infection. The estimated lifetime risk of cervical cancer is nevertheless relatively low (less than I in 20 for most community based studies). Although sensitivity and specificity of the available diagnostic techniques are suboptimal, Screening for persistent HPV infection is effective in reducing the incidence of cervical cancer. Infection can be detected by molecular techniques or by cytological examination of exfoliated cervical cells. Persistent infection is the single best predictor of risk of cervical cancer.(1) The latest findings of HPV and cervical cancer research need to be widely disseminated to the scientific and medical societies that are updating screening and management protocols, public health professionals, and to women and clinicians. This report reviews current evidence, clinical implications and directions for further research in the prevention, control and management of cervical cancer. We report the conclusions of the Experts' Meeting at the EUROGIN 2003 conference. (C) 2003 Wiley-Liss, Inc.

HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood

Here, we evaluated innate and adaptive immune system cytokine responses induced by HPV-16 L1 VLP in whole blood (WB) cultures from individuals receiving the vaccine (n = 20) or placebo (n = 4) before and after vaccination. 11 cytokines were measured: IL- 1 beta, IL-2, IL-4, IL-5, IL-6, IL-8, 1L- 10, IL- 12, IFN-gamma, TNF-alpha, and GM-CSF using multiplex bead arrays. Cytokine profiles from WB samples clearly discriminated between vaccine and placebo recipients and between pre and post-vaccination responses. Significant increases in Th1, Th2 and inflammatory cytokines were observed in WB assays following vaccination. Results from WB assays were compared against parallel PBMC-based assays in a subset of patients. Differences between whole blood assay and PBMC were observed, with the highest levels of induction found for WB for several cytokines. Our results indicate that multiplex assays for cytokine profiling in WB are an efficient toot for assessing broad spectrum, innate and adaptive immune responses to vaccines and identifying immunologic correlates of protection in efficacy studies. (c) 2005 Elsevier Ltd. All rights reserved.

Prophylactic HPV vaccines: Underlying mechanisms

Human papillomavirus virus-like particles (HPV VLP) can be generated by the synthesis and self-assembly in vitro of the major virus capsid protein L1. HPV L1 VLPs are morphologically and antigenically almost identical to native virions, and this technology has been exploited to produce HPV L1 VLP subunit vaccines. The vaccines elicit high titres of anti-L I VLP antibodies that persist at levels 10 times that of natural infections for at least 48 months. At present the assumption is that the protection achieved by these vaccines against incident HPV infection and HPV-associated ano-genital pathology is mediated via serum neutralising Immunoglobulin G (IgG). However, since there have been very few vaccine failures thus far, immune correlates of protection have not been established. The available evidence is that the immunodominant neutralising antibodies generated by L1 VLPs are type-specific and are not cross-neutralising, although highly homologous HPV pairs share minor cross-neutralisation epitopes. Important issues remaining to be addressed include the duration of protection and genotype replacement. (c) 2006 Elsevier Ltd. All rights reserved.